CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate

PartnershipPositive
AI Analysis

Summary

Roche has entered into a $2.3 billion licensing deal with Hanmi for a non-GLP-1 obesity candidate, diversifying its obesity pipeline and gaining entry into the lucrative obesity market.

Importance:7/10
Sentiment:
0.60
licensingobesitynon-GLP-1pipelinepartnership
Related Companies

Read the original article

Published by Pharmaceutical Technology on August 24, 2026 3:35 PM

Read Original